Peringatan Keamanan

Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D.

Dihydrotachysterol

DB01070

small molecule approved

Deskripsi

A vitamin D that can be regarded as a reduction product of vitamin D2.

Struktur Molekul 2D

Berat 398.6642
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

157 Data
Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.
Danazol Danazol may increase the hypercalcemic activities of Dihydrotachysterol.
Sucralfate The serum concentration of Sucralfate can be increased when it is combined with Dihydrotachysterol.
Orlistat Orlistat can cause a decrease in the absorption of Dihydrotachysterol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium sulfate The serum concentration of Magnesium sulfate can be increased when it is combined with Dihydrotachysterol.
Magnesium oxide The serum concentration of Magnesium oxide can be increased when it is combined with Dihydrotachysterol.
Magnesium salicylate The serum concentration of Magnesium salicylate can be increased when it is combined with Dihydrotachysterol.
Magaldrate The serum concentration of Magaldrate can be increased when it is combined with Dihydrotachysterol.
Magnesium hydroxide The serum concentration of Magnesium hydroxide can be increased when it is combined with Dihydrotachysterol.
Magnesium trisilicate The serum concentration of Magnesium trisilicate can be increased when it is combined with Dihydrotachysterol.
Magnesium chloride The serum concentration of Magnesium chloride can be increased when it is combined with Dihydrotachysterol.
Magnesium carbonate The serum concentration of Magnesium carbonate can be increased when it is combined with Dihydrotachysterol.
Talc The serum concentration of Talc can be increased when it is combined with Dihydrotachysterol.
Magnesium citrate The serum concentration of Magnesium citrate can be increased when it is combined with Dihydrotachysterol.
Magnesium silicate The serum concentration of Magnesium silicate can be increased when it is combined with Dihydrotachysterol.
Hydrotalcite The serum concentration of Hydrotalcite can be increased when it is combined with Dihydrotachysterol.
Magnesium aspartate The serum concentration of Magnesium aspartate can be increased when it is combined with Dihydrotachysterol.
Magnesium peroxide The serum concentration of Magnesium peroxide can be increased when it is combined with Dihydrotachysterol.
Magnesium gluconate The serum concentration of Magnesium gluconate can be increased when it is combined with Dihydrotachysterol.
Magnesium orotate The serum concentration of Magnesium orotate can be increased when it is combined with Dihydrotachysterol.
Magnesium The serum concentration of Magnesium can be increased when it is combined with Dihydrotachysterol.
Magnesium levulinate The serum concentration of Magnesium levulinate can be increased when it is combined with Dihydrotachysterol.
Magnesium lactate The serum concentration of Magnesium lactate can be increased when it is combined with Dihydrotachysterol.
Digoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Digoxin.
Acetyldigitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Acetyldigitoxin.
Deslanoside The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Deslanoside.
Ouabain The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Ouabain.
Digitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Digitoxin.
Oleandrin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Oleandrin.
Cymarin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Cymarin.
Proscillaridin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Proscillaridin.
Metildigoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Metildigoxin.
Lanatoside C The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Lanatoside C.
Gitoformate The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Gitoformate.
Acetyldigoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Acetyldigoxin.
Peruvoside The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Peruvoside.
Mineral oil Mineral oil can cause a decrease in the absorption of Dihydrotachysterol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methyclothiazide The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Dihydrotachysterol.
Bendroflumethiazide The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Dihydrotachysterol.
Benzthiazide The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Dihydrotachysterol.
Cyclothiazide The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Dihydrotachysterol.
Hydroflumethiazide The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Dihydrotachysterol.
Chlorothiazide The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Dihydrotachysterol.
Hydrochlorothiazide The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Dihydrotachysterol.
Trichlormethiazide The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Dihydrotachysterol.
Polythiazide The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Dihydrotachysterol.
Mebutizide The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Dihydrotachysterol.
Cyclopenthiazide The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Dihydrotachysterol.
Buthiazide The risk or severity of hypercalcemia can be increased when Buthiazide is combined with Dihydrotachysterol.
Calcitriol The risk or severity of adverse effects can be increased when Calcitriol is combined with Dihydrotachysterol.
Calcifediol The risk or severity of adverse effects can be increased when Calcifediol is combined with Dihydrotachysterol.
Ergocalciferol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Dihydrotachysterol.
Cholecalciferol The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Dihydrotachysterol.
Paricalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol.
Alfacalcidol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Alfacalcidol.
Seocalcitol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Seocalcitol.
Inecalcitol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Inecalcitol.
Becocalcidiol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Becocalcidiol.
Eldecalcitol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Eldecalcitol.
1alpha,24S-Dihydroxyvitamin D2 The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with 1alpha,24S-Dihydroxyvitamin D2.
Elocalcitol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Elocalcitol.
Maxacalcitol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Maxacalcitol.
Doxercalciferol The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Doxercalciferol.
Vitamin D The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Vitamin D.
1alpha-Hydroxyvitamin D5 The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with 1alpha-Hydroxyvitamin D5.
Previtamin D(3) The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Previtamin D(3).
Calcium acetate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium acetate.
Calcium glucoheptonate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium glucoheptonate.
Calcium chloride The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium chloride.
Calcium The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium.
Calcium carbonate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium carbonate.
Calcium citrate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium citrate.
Calcium gluconate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium gluconate.
Calcium Phosphate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium Phosphate.
Calcium glubionate anhydrous The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium glubionate anhydrous.
Calcium lactate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium lactate.
Calcium lactate gluconate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium lactate gluconate.
Calcium pangamate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium pangamate.
Calcium levulinate The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium levulinate.
Calcium cation The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium cation.
Calcium polycarbophil The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium polycarbophil.
Colestipol The serum concentration of Dihydrotachysterol can be decreased when it is combined with Colestipol.
Sevelamer The serum concentration of Dihydrotachysterol can be decreased when it is combined with Sevelamer.
Colesevelam The serum concentration of Dihydrotachysterol can be decreased when it is combined with Colesevelam.
Cholestyramine The serum concentration of Dihydrotachysterol can be decreased when it is combined with Cholestyramine.
Flunisolide The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Flunisolide.
Beclomethasone dipropionate The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Beclomethasone dipropionate.
Betamethasone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Betamethasone.
Fluticasone propionate The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Fluticasone propionate.
Fluocinolone acetonide The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Fluocinolone acetonide.
Triamcinolone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Triamcinolone.
Prednisone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Prednisone.
Fludrocortisone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Fludrocortisone.
Hydrocortisone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Hydrocortisone.
Prednisolone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Prednisolone.
Methylprednisolone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Methylprednisolone.
Trilostane The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Trilostane.
Budesonide The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Budesonide.
Dexamethasone The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Dexamethasone.
Corticotropin The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Corticotropin.

Target Protein

Vitamin D3 receptor VDR

Referensi & Sumber

Synthesis reference: von Werder, F.; U.S. Patent 2,228,491; January 14,1941; assigned to Winthrop Chemical Company, Inc.
Artikel (PubMed)
  • PMID: 15585789
    DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S.
  • PMID: 3320562
    Bosch R, Thijssen JH, Duursma SA: Action and metabolism of dihydrotachysterol2. J Steroid Biochem. 1987;27(4-6):829-36.
  • PMID: 6262039
    Pierides AM: Pharmacology and therapeutic use of vitamin D and its analogues. Drugs. 1981 Apr;21(4):241-56.
  • PMID: 4365509
    Gagnon R, Ogden GW, Just G, Kaye M: Comparison of dihydrotachysterol and 5,6-trans vitamin D3 on intestinal calcium absorption in patients with chronic renal failure. Can J Physiol Pharmacol. 1974 Apr;52(2):272-4.

Contoh Produk & Brand

Produk: 1 • International brands: 5
Produk
  • Hytakerol
    Capsule • .125 mg • Oral • Canada • Approved
International Brands
  • AT 10
  • Atiten — Bayer
  • Dihydral — Solvay
  • Dygratyl — Dishman
  • Tachystin — Chauvin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul